ClinConnect ClinConnect Logo
Search / Trial NCT06192654

Small Intestinal Submucosa Graft for Repair of Anterior Urethral Strictures

Launched by XIAOYONG ZENG · Dec 21, 2023

Trial Information

Current as of July 09, 2025

Enrolling by invitation

Keywords

Urethral Stricture

ClinConnect Summary

Urethral stricture refers to the abnormal narrowing of the urethral lumen resulting from fibrosis that affects the urethral epithelium and underlying corpus spongiosum. The management of urethral stricture longer than 2 cm a major therapeutic challenge in clinics. Currently available surgical techniques require harvesting of grafts from autologous sites. However, there are numerous disadvantages associated with autografts, such as limited availability and variable quality, donor site morbidity, increased risk of surgical complications; thereby the application of this method is especially li...

Gender

MALE

Eligibility criteria

  • Inclusion Criteria:
  • Patients signed informed consent form
  • Patients with a single, longer than 2.0 cm and shorter than or equal to 7.0 cm anterior urethral stricture
  • Patients undergoing substitution urethroplasty for urethral stricture.
  • Exclusion Criteria:
  • Patients without surgical indication
  • Subtotal and total urethral strictures
  • Radiation therapy to the abdomen or pelvis
  • Lichen sclerosis related strictures
  • Patients with previous hypospadias repair
  • Neurogenic urinary tract disorders
  • Mental disorders
  • Patients with a known biologic sensitivity or a cultural aversion to the use of porcine materials.
  • Patients with severe dysfunction of heart, lung, liver, kidney and other important organs , endocrine system and blood system.
  • Patient with malignant tumor
  • Patient who cannot be regularly examined due to any circumstances
  • Any clinical state which does not ensure the safe implementation of study procedure (investigator's view)

About Xiaoyong Zeng

Xiaoyong Zeng is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and innovation. With a background in biomedical sciences and extensive experience in clinical trial management, Zeng focuses on developing novel therapeutic approaches and enhancing patient outcomes. His leadership is characterized by a rigorous adherence to regulatory standards and ethical considerations, ensuring that all trials are conducted with the utmost integrity. Through collaboration with leading researchers and institutions, Zeng aims to contribute significantly to the understanding and treatment of various medical conditions, ultimately striving to improve healthcare solutions globally.

Locations

Wuhan, Hubei, China

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported